Device Trial Radar · NCT04774640
Development of a NIPTT for Detecting Copy Number Variations
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
May 29, 2014
Primary completion
Apr 30, 2018
Study completion Apr 30, 2018
Sponsor
- Lead sponsor
- Sequenom, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Columbia University
- First posted
- Mar 1, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- Female only, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To collect whole blood samples from pregnant women for the purpose of developing, optimizing and evaluating laboratory-developed noninvasive prenatal test (NIPT) for the detection of fetal chromosomal abnormalities of interest defined as microinsertions, microdeletions and other copy number variations (CNVs). The NIPT result will be compared to the test results obtained by microarray analysis of fetal cellular material obtained by amniocentesis or chorionic villus sampling.
Conditions
- Copy Number Variations
Interventions
MaterniT GENOMEDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of non-invasive pregnancy test (NIPT)Time frame: 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.